"From the moment we began discussions with Tethys, we were each struck by the complementary nature of our technologies, our core skills, and our sharp focus on addressing unmet clinical needs," Watkins said. "The Lipomics team is delighted to become part of Tethys, and to bring our expertise to bear on advancing the field of predictive personalized medicine."
About Tethys Bioscience
Tethys Bioscience is a predictive personalized medicine company developing novel tests which address the growing global healthcare challenge of chronic diseases such as diabetes. Founded in 2005, the company integrates an experienced management team, innovative research based on sound science, a CLIA-licensed clinical laboratory, and a commercialization team with extensive experience in diagnostic innovation. Our partnerships with world class researchers and our solid financial foundation will enable Tethys to help transform the management of chronic diseases by providing personalized, preventive solutions that aid every constituency: patients, doctors and the healthcare system as a whole.
Lipomics Technologies provides industry-leading metabolic assessments
for drug research, clinical diagnostics and personalized medicine. The
Company's proprietary analytical technologies generate comprehensive,
accurate and quantitative profiles of lipid metabolites. Lipomics delivers
deep and rich knowledge about biological and metabolic changes induced by
disease, drug action, nutritional or lifestyle influences. In partnership
with pharmaceutical, biotechnology, and nutrition companies, Lipomics uses
its technologies to discover new diagnostic biomarkers, improve dr
|SOURCE Tethys Bioscience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved